New hope for rare leukemia: Anthracycline-Free combo trial launches

NCT ID NCT06429098

Recruiting now Disease control Sponsor: The First Affiliated Hospital of Soochow University Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This study tests a combination of drugs (venetoclax plus azacitidine, decitabine, or cytarabine) without traditional anthracycline chemotherapy in 40 adults newly diagnosed with a specific genetic subtype of acute myeloid leukemia (CBFβ::MYH11-positive). The goal is to see if this gentler approach can achieve complete remission and reduce remaining cancer cells. The trial is currently recruiting participants.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: venetoclax combined with azacitidine, decitabine, or cytarabine
What this could lead to: If successful, this could offer a less toxic treatment option for people with this specific type of AML, potentially improving remission rates without using anthracyclines.
What could go wrong: This is a small, early-phase (Phase 2) trial with only 40 participants, so results may not apply to everyone. The combination may still cause side effects or fail to improve outcomes compared to standard care.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ACUTE MYELOID LEUKEMIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

acute myeloid leukemia core binding factor acute myeloid leukemia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ACUTE MYELOID LEUKEMIA

Contacts and locations

Locations

Ethical Committee of the First Affiliated Hospital of Soochow University
RECRUITING

Suzhou, Jiangsu, 215000, China
The First Affiliated Hospital of Soochow University, Jiangsu Institute of Hematology
RECRUITING

Suzhou, Jiangsu, 215000, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.